JP2012120458A - Cell separator - Google Patents

Cell separator Download PDF

Info

Publication number
JP2012120458A
JP2012120458A JP2010271802A JP2010271802A JP2012120458A JP 2012120458 A JP2012120458 A JP 2012120458A JP 2010271802 A JP2010271802 A JP 2010271802A JP 2010271802 A JP2010271802 A JP 2010271802A JP 2012120458 A JP2012120458 A JP 2012120458A
Authority
JP
Japan
Prior art keywords
point
container
outlet
cell separator
inlet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010271802A
Other languages
Japanese (ja)
Inventor
Nobuhiko Sato
伸彦 佐藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaneka Corp
Original Assignee
Kaneka Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaneka Corp filed Critical Kaneka Corp
Priority to JP2010271802A priority Critical patent/JP2012120458A/en
Publication of JP2012120458A publication Critical patent/JP2012120458A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02Blood transfusion apparatus
    • A61M1/0272Apparatus for treatment of blood or blood constituents prior to or for conservation, e.g. freezing, drying or centrifuging
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/04Liquids
    • A61M2202/0413Blood
    • A61M2202/0439White blood cells; Leucocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide a cell separator and a method for separating cells, which efficiently collect nucleated cells or monocytes from bodily fluid containing hemocyte components such as peripheral blood, cord blood and bone marrow.SOLUTION: The cell separator is composed of a container having an inlet and an outlet, and a nonwoven fabric which substantially captures nucleated cells but which erythrocytes substantially permeate. The nonwoven fabric is layered in the compressed state inside the container. This cell separator for separating nucleated cells or monocytes from the bodily fluid, and the method for separating cells by using the separator are provided. The inlet and the outlet are located opposite from each other with the nonwoven fabric in-between. The distance L from the center of gravity of a surface 1 to a point 1, when the surface on the inlet side of the container is the surface 1 and the point of contact between the inlet and the surface 1 is the point 1, is R/2 or smaller when the distance from the center of gravity of the surface 1 to the furthest point of the surface 1 is R. At the same time, the distance S from the center of gravity of a surface 2 to a point 2, when the surface on the outlet side of the container is the surface 2 and the point of contact between the outlet and the surface 2 is the point 2, is T/2 or smaller when the distance from the center of gravity of the surface 2 to the furthest point of the surface 2 is T.

Description

本発明は、末梢血、臍帯血、骨髄、組織抽出物、月経血など各血球成分を含む体液、及び、それらを祖分離した体液から、有核細胞を実質的に捕捉する細胞分離器を用いて有核細胞または単核球を分離する手段において、捕捉された有核細胞または単核球を効率的に回収することが出来る細胞分離器とそれを用いた細胞分離方法に関する。   The present invention uses a body fluid containing blood cell components such as peripheral blood, umbilical cord blood, bone marrow, tissue extract, menstrual blood, etc., and a cell separator that substantially captures nucleated cells from the body fluid from which they are separated. The present invention relates to a cell separator capable of efficiently collecting captured nucleated cells or mononuclear cells in a means for separating nucleated cells or mononuclear cells, and a cell separation method using the same.

近年、血液学や科学テクノロジーの急速な進歩に伴い、全血・骨髄・臍帯血・組織抽出物をはじめとする体液から必要な血液分画のみを分離して患者に投与することで治療効果をより高め、さらに、治療に必要のない分画は投与しないことで副作用をより抑制する、という治療スタイルが広く普及している。   In recent years, with rapid advances in hematology and scientific technology, only the necessary blood fractions are separated from body fluids such as whole blood, bone marrow, umbilical cord blood, and tissue extracts and administered to patients. A treatment style that further increases and further suppresses side effects by not administering fractions that are not necessary for treatment has become widespread.

例えば、血液輸血もその1つである。赤血球製剤は、出血および赤血球が不足する状態、または赤血球の機能低下により酸素が欠乏している場合に使用される血液製剤である。そのため異常な免疫反応や移植片対宿主病(GVHD)などの副作用を誘導する白血球は不要であり、除去する必要がある。場合によっては白血球に加えて血小板も除去することもある。   For example, blood transfusion is one of them. An erythrocyte product is a blood product that is used when bleeding and erythrocytes are deficient, or when oxygen is deficient due to reduced function of erythrocytes. Therefore, leukocytes that induce side effects such as abnormal immune responses and graft-versus-host disease (GVHD) are unnecessary and need to be removed. In some cases, platelets may be removed in addition to leukocytes.

一方、血小板製剤は、血液凝固因子の欠乏による出血ないし出血傾向にある患者に使用される血液製剤である。遠心分離により、血小板以外の不要な細胞や成分は除去され、必要とされる血小板成分のみを採取している。   On the other hand, a platelet preparation is a blood preparation used for patients who are bleeding or tend to bleed due to a lack of blood coagulation factors. Centrifugation removes unnecessary cells and components other than platelets and collects only the necessary platelet components.

加えて近年、白血病や固形癌治療に向けた造血幹細胞移植が盛んに行われるようになり、治療に必要な細胞(造血幹細胞を含む白血球群)を分離し投与するようになってきた。この造血幹細胞のソースとして、ドナーの負担が少ない、増殖能力が優れている等の利点から、骨髄や末梢血に加えて臍帯血も注目を浴びている。また近年、月経血中にも幹細胞が豊富に存在することが示唆され、これまで廃棄されていた月経血も貴重な幹細胞ソースとして利用される可能性がある。   In addition, in recent years, hematopoietic stem cell transplantation for leukemia and solid cancer treatment has been actively performed, and cells necessary for treatment (a group of leukocytes containing hematopoietic stem cells) have been separated and administered. As a source of this hematopoietic stem cell, umbilical cord blood is attracting attention in addition to bone marrow and peripheral blood because of its advantages such as low burden on donors and excellent proliferation ability. In recent years, it has been suggested that there are abundant stem cells in menstrual blood, and menstrual blood that has been discarded may be used as a valuable source of stem cells.

骨髄や末梢血に関して、不要な細胞を除き白血球を分離・純化して投与することが望まれている一方で、臍帯血についても血縁者のためのバンキングが盛んになり、使用時まで凍結保存する必要性から、凍結保存による赤血球溶血を防ぐことを目的に白血球は分離・純化されている。   For bone marrow and peripheral blood, it is desirable to separate and purify leukocytes after removing unnecessary cells, but umbilical cord blood is also becoming popular for banking for relatives and is stored frozen until use. From the necessity, leukocytes are separated and purified for the purpose of preventing red blood cell hemolysis due to cryopreservation.

分離方法としてはフィコールを用いた比重液による遠心分離法や赤血球沈降剤であるヒドロキシエチルスターチを用いた遠心分離法が提案されているが、閉鎖系での処理が不可能であり異物や菌が混入すること、処理するのに要する時間長いことなどの問題を有している。   As a separation method, a centrifugal separation method using a specific gravity liquid using Ficoll and a centrifugal separation method using hydroxyethyl starch, which is an erythrocyte sedimentation agent, have been proposed. There are problems such as mixing and a long time required for processing.

遠心分離法を用いない細胞分離方法として、最近では、赤血球と血小板は捕捉されず白血球のみを捕捉するフィルター材料を用いて白血球を除去する方法(特許文献1、特許文献2)も報告されており、現在主流となっている白血球除去フィルター(旭化成メディカル株式会社製「セパセル」、ポール社製「ピュアセルRC」等)では、フィルター面に対して液の入口と出口の位置が面の中心から外れる、いわゆるクロスフロータイプが採用されている。   As a cell separation method that does not use a centrifugal separation method, a method of removing leukocytes using a filter material that captures only white blood cells without capturing red blood cells and platelets has recently been reported (Patent Document 1, Patent Document 2). In the leukocyte removal filters that are currently mainstream (such as “Sepacel” manufactured by Asahi Kasei Medical Co., Ltd., “Pure Cell RC” manufactured by Paul Co., Ltd.), the position of the liquid inlet and outlet from the center of the surface deviates from the center of the surface. A so-called cross flow type is adopted.

さらに、クロスフロータイプの中でも、細胞を効率的に捕捉可能な形状が検討されている(特許文献3)が、それら白血球除去フィルターで使用できる回収液は限られており、低粘度の回収液を使用すると細胞の回収率が低下するのが問題であった。また、高粘度の回収液を用いた場合にも、使用するためには遠心して溶液置換する必要があり、用途が制限されるという問題もあった。   Furthermore, among cross-flow types, shapes that can efficiently capture cells have been studied (Patent Document 3), but there are limited recovery solutions that can be used with these leukocyte removal filters. When used, the problem was that the cell recovery rate decreased. In addition, even when a high-viscosity recovery liquid is used, it is necessary to perform solution replacement by centrifuging in order to use it.

特表2001−518792Special table 2001-518792 国際公開番号WO98/32840International Publication Number WO98 / 32840 特開平11−266852JP-A-11-266852

本発明の目的は、末梢血、臍帯血、骨髄、組織抽出物、月経血など各血球成分を含む体液、及び、それらを祖分離した体液から、有核細胞を実質的に捕捉する細胞分離器を用いて有核細胞または単核球を分離する手段において、捕捉された有核細胞または単核球を効率的に回収することが出来、且つ、回収液に依存しない細胞分離器と細胞分離方法を提供することである。   An object of the present invention is to provide a body fluid containing each blood cell component such as peripheral blood, umbilical cord blood, bone marrow, tissue extract, menstrual blood, etc., and a cell separator that substantially captures nucleated cells from the body fluid separated from them. Separating nucleated cells or mononuclear cells by using a cell separator and cell separation method capable of efficiently recovering captured nucleated cells or mononuclear cells and not depending on the recovery solution Is to provide.

本発明者は、従来検討されていない、捕捉された有核細胞または単核球を効率的に回収することが出来、且つ、回収液に依存しない細胞分離器と細胞分離方法に関して検討を行った結果、以下に示す細胞分離器及び細胞分離方法が効果的であることを見出し、本発明を完成するに至った。   The present inventor has studied a cell separator and a cell separation method that can efficiently recover captured nucleated cells or mononuclear cells, which have not been studied in the past, and that do not depend on the recovery solution. As a result, the following cell separator and cell separation method were found to be effective, and the present invention was completed.

即ち本発明は、(1)入口と出口を有する容器と、有核細胞を実質的に捕捉し赤血球は実質的に通過する不織布から構成され、前記容器内に前記不織布が圧縮された状態で積層された体液から有核細胞または単核球を分離する細胞分離器であって、前記入口と前記出口とが、前記不織布を挟んでそれぞれ逆方向に位置し、前記容器の前記入口側の面を面1とし、前記入口と前記面1とが接触する点を点1とし、面1の重心から点1までの距離Lが、面1の重心から面1の最遠点までの距離をRとしたとき、LがR/2以下であることを特徴とし、且つ、前記容器の前記出口側の面を面2とし、前記出口と前記面2とが接触する点を点2とし、面2の重心から点2までの距離Sが、面2の重心から面2の最遠点までの距離をTとしたとき、SがT/2以下であることを特徴とする細胞分離器
(2)捕捉された有核細胞を剥離回収させる手段において、体液の出口から溶液を導入し、入口より捕捉された有核細胞を回収することを含む(1)に記載の細胞分離器
(3)容器の面2に対する出口の角度αが45度より大きく135度より小さいことを特徴とする(1)または(2)に記載の細胞分離器
(4)容器の面2に対する出口の角度αが垂直であることを特徴とする(1)または(2)に記載の細胞分離器
(5)血小板も実質的に捕捉する不織布が積層された(1)から(4)のいずれかに記載の細胞分離器。
(6)分離された有核細胞が単核球を含むことを特徴とする(1)から(5)のいずれかに記載の細胞分離器
(7)(1)から(6)のいずれかに記載の細胞分離器を用いることを特徴とする、細胞分離方法
(8)低粘度の回収液を用いることを特徴とする、(7)に記載の細胞分離方法
(9)回収液が生理食塩水、細胞培養用培地、ヒドロキシエチルスターチ、デキストランを含む溶液であることを特徴とする、(8)に記載の細胞分離方法
であり、本発明の細胞分離器と細胞分離方法を用いると、従来より効率良く有核細胞または単核球を回収でき、尚且つ、回収液による依存も少ない。
That is, the present invention comprises (1) a container having an inlet and an outlet, and a nonwoven fabric that substantially captures nucleated cells and substantially passes red blood cells, and the nonwoven fabric is laminated in a compressed state in the container. A cell separator for separating nucleated cells or mononuclear cells from the body fluid, wherein the inlet and the outlet are respectively positioned in opposite directions across the nonwoven fabric, and the surface on the inlet side of the container Let point 1 be the point where the entrance and the surface 1 are in contact with each other, the distance L from the center of gravity of the surface 1 to the point 1 is R, and the distance from the center of gravity of the surface 1 to the farthest point of the surface 1 is R L is equal to or less than R / 2, the surface on the outlet side of the container is the surface 2, the point where the outlet and the surface 2 are in contact is the point 2, When the distance S from the center of gravity to point 2 is T and the distance from the center of gravity of surface 2 to the farthest point of surface 2 is T, S is / 2 or less cell separator (2) In the means for separating and collecting the captured nucleated cells, the solution is introduced from the outlet of the body fluid, and the captured nucleated cells are recovered from the inlet (3) The cell separator according to (1) or (2), wherein the angle α of the outlet with respect to the surface 2 of the container is greater than 45 degrees and smaller than 135 degrees (4) The cell separator according to (1) or (2), wherein the outlet angle α with respect to the surface 2 of the container is vertical (5) laminated with a nonwoven fabric that substantially captures platelets ( The cell separator according to any one of 1) to (4).
(6) The cell separator (7) (1) to (6) according to any one of (1) to (5), wherein the separated nucleated cells contain mononuclear cells. A cell separation method according to (7), characterized in that the cell separation method described in (7) is used, and a cell separation method according to (7), wherein the recovery solution is a physiological saline. The cell separation method according to (8), which is a solution containing a cell culture medium, hydroxyethyl starch, and dextran. When the cell separator and the cell separation method of the present invention are used, Nucleated cells or mononuclear cells can be efficiently recovered, and there is little dependence on the recovery solution.

本発明によれば、末梢血、臍帯血、骨髄、組織抽出物、月経血など各血球成分を含む体液またはそれらを粗分離した体液中から有核細胞を分離する細胞分離手段において、捕捉した有核細胞または単核球を高収率で回収でき、尚且つ、幅広い回収液を使用できるため、回収細胞の使用用途も格段に広まる。   According to the present invention, the trapped organic substance is separated in a body fluid containing each blood cell component such as peripheral blood, umbilical cord blood, bone marrow, tissue extract, menstrual blood, etc. or a cell separation means for separating nucleated cells from the body fluid roughly separated therefrom. Nucleic cells or mononuclear cells can be recovered with a high yield, and a wide range of recovery liquids can be used.

面1におけるL、Rを説明した図The figure explaining L and R in plane 1 面2におけるS、Tを説明した図The figure explaining S and T in plane 2 面2に対する出口の角度αを説明した図The figure explaining the angle α of the exit with respect to the surface 2 本発明における容器の形状Shape of container in the present invention 回路を供えた細胞分離器の例Example of a cell separator with a circuit (a)実施例に用いた容器、(b)比較例に用いた容器(A) Container used in Examples, (b) Container used in Comparative Examples 実施例での白血球回収率Leukocyte recovery rate in the examples 比較例での白血球回収率White blood cell recovery rate in the comparative example

以下に本発明について詳細に説明するが、本発明は以下の説明に限定されるものではない。   The present invention will be described in detail below, but the present invention is not limited to the following description.

本発明における体液とは、末梢血、骨髄、臍帯血、月経血、組織抽出物を意味し、それらを粗分離したものであっても構わない。また動物種に関しても制限は無く、ヒト、ウシ、マウス、ラット、ブタ、サル、イヌ、ネコなど哺乳動物であれば何であっても構わない。さらに体液の抗凝固剤の種類も問わず、ACD(acid-citrate-dextrose)液、CPD(citrate-phosphate-dextrose)液、CPDA(citrate-phosphate-dextrose-adenine)液などのクエン酸抗凝固であってもヘパリン、低分子ヘパリン、フサン(メチル酸ナファモスタット)、EDTAで抗凝固していても良い。使用する目的に応じて影響がなければ体液の保存条件も一切問わない。   The bodily fluid in the present invention means peripheral blood, bone marrow, umbilical cord blood, menstrual blood, and tissue extract, and these may be roughly separated. There are no restrictions on animal species, and any animal may be used as long as it is a mammal such as a human, cow, mouse, rat, pig, monkey, dog, or cat. In addition, regardless of the type of anticoagulant in body fluids, citrate anticoagulation such as ACD (acid-citrate-dextrose), CPD (citrate-phosphate-dextrose), and CPDA (citrate-phosphate-dextrose-adenine) It may be anticoagulated with heparin, low molecular weight heparin, fusan (nafamostat methyl acid) or EDTA. If there is no influence depending on the purpose of use, the preservation conditions of body fluids are not questioned at all.

本発明において、細胞分離器に充填される細胞分離材は特に制限されないが、滅菌耐性や細胞への安全性の観点からは、ポリエチレンテレフタート、ポリブチレンテレフタレート、ポリエチレン、高密度ポリエチレン、低密度ポリエチレン、ポリビニルアルコール、塩化ビニリデン、レーヨン、ビニロン、ポリプロピレン、アクリル(ポリメチルメタクリレート、ポリヒドロキシエチルメタクリレート、ポリアクリルニトリル、ポリアクリル酸、ポリアクリレート)、ナイロン、ポリイミド、アラミド(芳香族ポリアミド)、ポリアミド、キュプラ、カーボン、フェノール、ポリエステル、パルプ、麻、ポリウレタン、ポリスチレン、ポリカーボネートなどの合成高分子、アガロース、セルロース、セルロースアセテート、キトサン、キチンなどの天然高分子、ガラスなどの無機材料や金属等が挙げられる。   In the present invention, the cell separation material filled in the cell separator is not particularly limited, but from the viewpoint of sterilization resistance and cell safety, polyethylene terephthalate, polybutylene terephthalate, polyethylene, high-density polyethylene, low-density polyethylene. , Polyvinyl alcohol, vinylidene chloride, rayon, vinylon, polypropylene, acrylic (polymethyl methacrylate, polyhydroxyethyl methacrylate, polyacrylonitrile, polyacrylic acid, polyacrylate), nylon, polyimide, aramid (aromatic polyamide), polyamide, cupra , Synthetic polymers such as carbon, phenol, polyester, pulp, hemp, polyurethane, polystyrene, polycarbonate, agarose, cellulose, cellulose acetate, chitosan, chitin Which natural polymers, inorganic materials and metals, such as glass.

好ましくはポリエチレンテレフタレート、ポリブチレンテレフタレート、ポリプロピレン、アクリル、ナイロン、ポリウレタン、ガラスである。これらの材料は一種類の単独とは限らず、必要に応じて材料を複合・混合・融合して用いても良い。さらには必要ならば、蛋白質、ペプチド、アミノ酸、糖類など特定の細胞に親和性のある分子を固定しても構わない。   Preferred are polyethylene terephthalate, polybutylene terephthalate, polypropylene, acrylic, nylon, polyurethane, and glass. These materials are not limited to a single type, and may be combined, mixed, and fused as necessary. Furthermore, if necessary, molecules having affinity for specific cells such as proteins, peptides, amino acids and saccharides may be immobilized.

本発明の細胞分離器は、捕捉された細胞を効率的に回収するために、以下の点を有することを特徴とする。(1)入口と出口を有する容器と、有核細胞を実質的に捕捉し赤血球は実質的に通過する不織布から構成され、前記容器内に前記不織布が圧縮された状態で積層されていること。(2) 前記入口と前記出口とが、前記不織布を挟んでそれぞれ逆方向に位置していること。(3)前記容器の前記入口側の面を面1とし、前記入口と前記面1とが接触する点を点1とし、面1の重心から点1までの距離Lが、面1の重心から面1の最遠点までの距離をRとしたとき、LがR/2以下であること。(3)前記容器の前記出口側の面を面2とし、前記出口と前記面2とが接触する点を点2とし、面2の重心から点2までの距離Sが、面2の重心から面2の最遠点までの距離をTとしたとき、SがT/2以下であること。   The cell separator of the present invention is characterized by having the following points in order to efficiently collect captured cells. (1) A container having an inlet and an outlet, and a nonwoven fabric that substantially captures nucleated cells and substantially passes red blood cells, and the nonwoven fabric is laminated in a compressed state in the container. (2) The said inlet and the said outlet are each located in the reverse direction on both sides of the said nonwoven fabric. (3) A surface on the inlet side of the container is a surface 1, a point where the inlet and the surface 1 are in contact is a point 1, and a distance L from the center of gravity of the surface 1 to the point 1 is from the center of gravity of the surface 1 L is R / 2 or less, where R is the distance to the farthest point on the surface 1. (3) The surface on the outlet side of the container is the surface 2, the point where the outlet and the surface 2 are in contact is the point 2, and the distance S from the center of gravity of the surface 2 to the point 2 is from the center of gravity of the surface 2 S is T / 2 or less, where T is the distance to the farthest point on surface 2.

LがR/2より大きい、または、SがT/2より大きい場合は、低粘度の回収液を用いた場合に有意に有核細胞の回収率が低下するが、LがR/2以下、SがT/2以下の場合には、低粘度の回収液であっても有核細胞の回収率は低下しない。これは、入口や出口が各面に於いて面の端に位置していると回収液が細胞分離器全体に行き渡らないため回収率が低下すると考えられる。   When L is greater than R / 2 or S is greater than T / 2, the recovery rate of nucleated cells is significantly reduced when a low-viscosity recovery solution is used, but L is R / 2 or less, When S is T / 2 or less, the recovery rate of nucleated cells does not decrease even with a low viscosity recovery solution. This is thought to be because the recovery rate decreases because the recovery solution does not reach the entire cell separator when the inlet and the outlet are located at the end of each surface.

更には、本発明の細胞分離器は、容器の面2に対する出口の角度αが45度より大きく135度より小さいという特徴も有する。容器の面2に対する出口の角度αが0度以上45度未満または135度より大きく180度以下の場合は、低粘度の回収液を用いると有意に有核細胞の回収率が低下するが、容器の面2に対する出口の角度αが45度より大きく135度より小さい場合には、低粘度の回収液であっても細胞の回収率は低下しない。これは、容器の面2に対する出口の角度αが45度より大きく135度より小さい場合には細胞分離器全体に液が拡散されるが、容器の面2に対する出口の角度αが0度以上45度以下または135度以上180度以下の場合には回収液が局所的にしか流れなくなるためであると考えられる。   Furthermore, the cell separator of the present invention is characterized in that the angle α of the outlet with respect to the surface 2 of the container is larger than 45 degrees and smaller than 135 degrees. When the angle α of the outlet with respect to the surface 2 of the container is 0 degree or more and less than 45 degrees or more than 135 degrees and 180 degrees or less, the recovery rate of nucleated cells is significantly reduced by using a low-viscosity recovery liquid. When the angle α of the outlet with respect to the surface 2 is greater than 45 degrees and smaller than 135 degrees, the recovery rate of cells does not decrease even with a low viscosity recovery solution. This is because when the outlet angle α with respect to the surface 2 of the container is larger than 45 degrees and smaller than 135 degrees, the liquid is diffused throughout the cell separator, but the outlet angle α with respect to the surface 2 of the container is 0 degree or more and 45 degrees. This is considered to be because the recovered liquid flows only locally when the angle is less than or equal to 135 degrees or less than or equal to 135 degrees or less.

本発明で規定する面1の重心から点1までの距離L、面1の重心から面1の最遠点までの距離R、面2の重心から点2までの距離S、面2の重心から面2の最遠点までの距離Tは、図1または図2に示した通りである。また角度αは図3に示した通りである。   From the distance L from the center of gravity of surface 1 to point 1 defined by the present invention, the distance R from the center of gravity of surface 1 to the farthest point of surface 1, the distance S from the center of gravity of surface 2 to point 2, and the center of gravity of surface 2 The distance T to the farthest point of the surface 2 is as shown in FIG. 1 or FIG. The angle α is as shown in FIG.

また、本発明において実質的に赤血球が通過するとは処理した体液のうち60%以上が不織布を通過することを意味し、実質的に有核細胞が実質的に捕捉されるとは処理した体液のうち60%以上が不織布に捕捉されることを意味する。
また、本発明における容器は、図4に示したように円柱、四角柱、楕円柱、ひし形中など如何なる形状であっても構わない。その容器の形状に応じて不織布を切り取る、または不織布の形状に応じて容器を選択すれば良い。また圧縮された状態で不織布を積層して充填、すなわち、上記容器において全ての方向に対して不織布が圧縮されていても良く、一方向、例えば図4の矢印に示したような方向に圧縮されていても構わない。入口と出口の位置は圧縮された方向に、図4でいう矢印の面に於いて不織布を挟んで位置している方が好ましいが、本発明はこれらに限定されない。
In the present invention, the fact that red blood cells substantially pass means that 60% or more of the treated body fluid passes through the nonwoven fabric, and that substantially nucleated cells are substantially captured means that the treated body fluid It means that 60% or more of them are captured by the nonwoven fabric.
Further, the container in the present invention may have any shape such as a cylinder, a quadrangular column, an elliptical column, or a rhombus as shown in FIG. The nonwoven fabric may be cut out according to the shape of the container, or the container may be selected according to the shape of the nonwoven fabric. In addition, the nonwoven fabric may be laminated and filled in a compressed state, that is, the nonwoven fabric may be compressed in all directions in the container, and compressed in one direction, for example, the direction shown by the arrow in FIG. It does not matter. The inlet and outlet positions are preferably positioned in the compressed direction, with the nonwoven fabric sandwiched between the arrows in FIG. 4, but the present invention is not limited to these.

本発明の細胞分離器を用いて閉鎖的に細胞を分離するために、以下に示す回路を用いることも可能である。つまり入口側にバッグと接続可能なコネクター、例えばびん針が少なくとも1つ備わっている、または入口側に血液又はプライミング液を収容するバッグを少なくとも1つ備わっており、更に出口側には細胞分離器を通過した液を収容するためのバッグが備わった回路が付属されていても良い。出口側に捕捉された細胞を回収するためのシリンジ接続部、入口側に捕捉された細胞を収容するための回収バッグが付属されている回路を備えている方がより好ましい。またこれらの回路は液の流れを制御するために、三方活栓、ローラークレンメ、クランプなども備えている方がより好ましい。図5に閉鎖系で処理するための回路を備えた細胞分離器を例示した。但し、本発明はこれらに限定されるものではない。   In order to isolate cells in a closed manner using the cell separator of the present invention, the following circuit can be used. That is, at least one connector that can be connected to the bag on the inlet side, for example, a bottle needle, or at least one bag that contains blood or priming liquid is provided on the inlet side, and a cell separator on the outlet side. A circuit having a bag for containing the liquid that has passed through the container may be attached. It is more preferable to provide a circuit with a syringe connection part for collecting the cells captured on the outlet side and a collection bag for accommodating the cells captured on the inlet side. These circuits are also preferably provided with a three-way stopcock, a roller clamp, a clamp and the like in order to control the flow of the liquid. FIG. 5 illustrates a cell separator having a circuit for processing in a closed system. However, the present invention is not limited to these.

また、本発明は、本発明の細胞分離器を用いた細胞分離方法も提供する。特に、低粘度の回収液を用いる際には、本発明の細胞分離器の利用が望ましい。低粘度の回収液とは、粘度が8mPa・S以下の回収液を意味し、例えば、生理食塩水や細胞培養用培地、ヒドロキシエチルスターチ、デキストランを含む溶液が挙げられる。好ましくは7mPa・S以下、より好ましくは6mPa・s以下である。細胞培養用培地としては、例えば、Dulbecco MEM(日水)、α−MEM(GIBCO BRL社製)、MEM(日水)、IMEM(日水)、RPMI−1640(日水)培地等が代表的なものとして挙げられるがこれらに限定されない。更にこれらの回収液にはアルブミンやFBSなどの蛋白質が含まれていても構わない。   The present invention also provides a cell separation method using the cell separator of the present invention. In particular, when using a low-viscosity recovery liquid, it is desirable to use the cell separator of the present invention. The low-viscosity recovery liquid means a recovery liquid having a viscosity of 8 mPa · S or less, and examples thereof include a solution containing physiological saline, a cell culture medium, hydroxyethyl starch, and dextran. Preferably it is 7 mPa * S or less, More preferably, it is 6 mPa * s or less. Typical examples of the cell culture medium include Dulbecco MEM (Nissui), α-MEM (GIBCO BRL), MEM (Nissui), IMEM (Nissui), RPMI-1640 (Nissui) medium, and the like. However, it is not limited to these. Furthermore, these recovered liquids may contain proteins such as albumin and FBS.

以下、実施例において本発明に関して詳細に述べるが、本発明は以下の実施例のみに限定されるものではない。   EXAMPLES Hereinafter, although an Example demonstrates in detail regarding this invention, this invention is not limited only to a following example.

(実施例1)
厚さ(内径)9mm、直径(内径)32mmの円柱型の容器に、直径32mmの円形に切断したポリブチレンテレフタレート製不織布(繊維径2.7マイクロメートル)76枚を圧縮した状態で積層し細胞分離器を作成した。これは、図4に示したような円柱形の容器であり、矢印に示した方向に不織布を圧縮して充填した。具体的な細胞分離器の形は図6(a)に示した通りである。まず始めに生理食塩水50mLをシリンジにとり、手押しで前記容器の入口より導入し、通液した。次にCPD抗凝固の新鮮ウシ血液80mL(CPD:血液=200:28で混合した12%CPDを含むウシ末梢血)を15mL/minの流速で、次いで生理食塩水15mLを同様に15mL/minの流速でシリンジポンプを用いて通血した。その後、通液とは逆に出口側より10%ACD−A液と10%FBSを含むαMEM培地30mLをシリンジを用いて手押しして、入口側より回収した。処理前血液の血算、回収した溶液の血算を血球カウンター(シスメックス、K−4500)により測定し、白血球の回収率を算出した。結果は表1、図7に示した。
Example 1
Cells are laminated in a compressed state with 76 sheets of non-woven polybutylene terephthalate (fiber diameter: 2.7 micrometers) cut into a circular shape with a diameter of 32 mm in a cylindrical container having a thickness (inner diameter) of 9 mm and a diameter (inner diameter) of 32 mm. A separator was created. This is a cylindrical container as shown in FIG. 4, and the nonwoven fabric was compressed and filled in the direction indicated by the arrow. The specific shape of the cell separator is as shown in FIG. First, 50 mL of physiological saline was taken in a syringe, introduced by hand from the inlet of the container, and passed through. Next, 80 ml of CPD anticoagulated fresh bovine blood (bovine peripheral blood containing 12% CPD mixed with CPD: blood = 200: 28) at a flow rate of 15 ml / min, and then 15 ml of physiological saline at 15 ml / min in the same manner. Blood was passed using a syringe pump at a flow rate. Then, contrary to liquid flow, 30 mL of αMEM medium containing 10% ACD-A solution and 10% FBS was manually pushed from the outlet side and collected from the inlet side. The blood count of the blood before treatment and the blood count of the collected solution were measured with a blood cell counter (Sysmex, K-4500), and the leukocyte recovery rate was calculated. The results are shown in Table 1 and FIG.

(実施例2)
回収液として10%ACD−A液と10%FBSを含むαMEM培地30mLの代わりに10%ACD−A液と4%ヒト血清アルブミンを含むデキストラン糖注を用いること以外は実施例1と同様に実施した。結果は表1、図7に示した。
(Example 2)
The same procedure as in Example 1 was carried out except that a dextran sugar injection containing 10% ACD-A solution and 4% human serum albumin was used instead of 30 mL of αMEM medium containing 10% ACD-A solution and 10% FBS as the recovery solution. did. The results are shown in Table 1 and FIG.

(実施例3)
回収液として10%ACD−A液と10%FBSを含むαMEM培地30mLの代わりに10%ACD−A液と4%ヒト血清アルブミンを含むサリンヘスを用いること以外は実施例1と同様に実施した。結果は表1、図7に示した。
(Example 3)
The same procedure as in Example 1 was carried out except that sarinhes containing 10% ACD-A solution and 4% human serum albumin was used in place of 30 mL of αMEM medium containing 10% ACD-A solution and 10% FBS. The results are shown in Table 1 and FIG.

(実施例4)
回収液として10%ACD−A液と10%FBSを含むαMEM培地30mLの代わりに10%ACD−A液添加生理食塩水を用いること以外は実施例1と同様に実施した。結果は表1、図7に示した。
Example 4
The same procedure as in Example 1 was performed except that 10% ACD-A solution-added physiological saline was used in place of 30 mL of αMEM medium containing 10% ACD-A solution and 10% FBS as the collected solution. The results are shown in Table 1 and FIG.

(比較例1)
厚さ(内径)9mm、一辺(内径)30mmの四角柱型の容器に、一辺30mmの四角形に切断したポリブチレンテレフタレート製不織布(繊維径2.7マイクロメートル)76枚を圧縮した状態で積層し細胞分離器を作成した。これは、図4に示したような四角柱形の容器であり、矢印に示した方向に不織布を圧縮して充填した。具体的な細胞分離器の形は図6(b)に示した通りである。まず始めに生理食塩水50mLをシリンジにとり、手押しで前記容器の入口より導入し、通液した。次にCPD抗凝固の新鮮ウシ血液80mL(CPD:血液=200:28で混合した12%CPDを含むウシ末梢血)を15mL/minの流速で、次いで生理食塩水15mLを同様に15mL/minの流速でシリンジポンプを用いて通血した。その後、通液とは逆に出口側より10%ACD−A液と10%FBSを含むαMEM培地30mLをシリンジを用いて手押しして、入口側より回収した。処理前血液の血算、回収した溶液の血算を血球カウンター(シスメックス、K−4500)により測定し、白血球の回収率を算出した。結果は表2、図8に示した。
(Comparative Example 1)
Laminated 76 sheets of polybutylene terephthalate nonwoven fabric (fiber diameter: 2.7 micrometers) cut into a square with a side of 30 mm in a rectangular column type container with a thickness (inner diameter) of 9 mm and a side (inner diameter) of 30 mm. A cell separator was created. This was a quadrangular prism-shaped container as shown in FIG. 4, and the nonwoven fabric was compressed and filled in the direction indicated by the arrow. The specific shape of the cell separator is as shown in FIG. First, 50 mL of physiological saline was taken in a syringe, introduced by hand from the inlet of the container, and passed through. Next, 80 mL of CPD anticoagulated fresh bovine blood (bovine peripheral blood containing 12% CPD mixed at CPD: blood = 200: 28) was flowed at a flow rate of 15 mL / min, and then 15 mL of physiological saline was similarly added at 15 mL / min. Blood was passed using a syringe pump at a flow rate. Then, contrary to liquid flow, 30 mL of αMEM medium containing 10% ACD-A solution and 10% FBS was manually pushed from the outlet side and collected from the inlet side. The blood count of the blood before treatment and the blood count of the collected solution were measured with a blood cell counter (Sysmex, K-4500), and the leukocyte recovery rate was calculated. The results are shown in Table 2 and FIG.

(比較例2)
回収液として10%ACD−A液と10%FBSを含むαMEM培地30mLの代わりに10%ACD−A液と4%ヒト血清アルブミンを含むサリンヘスを用いること以外は実施例1と同様に実施した。結果は表2、図8に示した。
(Comparative Example 2)
The same procedure as in Example 1 was carried out except that sarinhes containing 10% ACD-A solution and 4% human serum albumin was used in place of 30 mL of αMEM medium containing 10% ACD-A solution and 10% FBS. The results are shown in Table 2 and FIG.

(比較例3)
回収液として10%ACD−A液と10%FBSを含むαMEM培地30mLの代わりに10%ACD−A液添加生理食塩水を用いること以外は実施例1と同様に実施した。結果は表2、図8に示した。
(Comparative Example 3)
The same procedure as in Example 1 was performed except that 10% ACD-A solution-added physiological saline was used in place of 30 mL of αMEM medium containing 10% ACD-A solution and 10% FBS as the collected solution. The results are shown in Table 2 and FIG.

1.プライミング溶液が収容された容器と接続可能なコネクターおよびプライミング溶液を収容する容器
2.シリンジと接続可能なコネクター
3.細胞分離器
4.体液が収容された容器と接続可能なコネクターおよび体液を収容する容器
5.廃液バッグ
6.回収バッグ
1. 1. Connector that can be connected to a container containing the priming solution and a container containing the priming solution 2. Connector that can be connected to a syringe Cell separator 4. 4. A connector that can be connected to a container containing body fluid and a container that contains body fluid. Waste liquid bag Collection bag

Claims (9)

入口と出口を有する容器と、有核細胞を実質的に捕捉し赤血球は実質的に通過する不織布から構成され、前記容器内に前記不織布が圧縮された状態で積層された体液から有核細胞または単核球を分離する細胞分離器であって、前記入口と前記出口とが、前記不織布を挟んでそれぞれ逆方向に位置し、前記容器の前記入口側の面を面1とし、前記入口と前記面1とが接触する点を点1とし、面1の重心から点1までの距離Lが、面1の重心から面1の最遠点までの距離をRとしたとき、LがR/2以下であることを特徴とし、且つ、前記容器の前記出口側の面を面2とし、前記出口と前記面2とが接触する点を点2とし、面2の重心から点2までの距離Sが、面2の重心から面2の最遠点までの距離をTとしたとき、SがT/2以下であることを特徴とする細胞分離器。 A container having an inlet and an outlet, and a non-woven fabric that substantially captures nucleated cells and substantially passes erythrocytes; A cell separator for separating mononuclear cells, wherein the inlet and the outlet are positioned in opposite directions across the nonwoven fabric, the inlet-side surface of the container is a surface 1, and the inlet and the The point where the surface 1 is in contact is point 1, and the distance L from the center of gravity of the surface 1 to point 1 is R, and the distance from the center of gravity of the surface 1 to the farthest point of the surface 1 is R / 2. The surface on the outlet side of the container is a surface 2, the point where the outlet and the surface 2 are in contact is a point 2, and the distance S from the center of gravity of the surface 2 to the point 2 Where S is T / 2 or less, where T is the distance from the center of gravity of surface 2 to the farthest point of surface 2 Cells separator characterized. 捕捉された有核細胞を剥離回収させる手段において、体液の出口から溶液を導入し、入口より捕捉された有核細胞を回収することを含む請求項1に記載の細胞分離器。 The cell separator according to claim 1, wherein the means for separating and collecting the captured nucleated cells comprises introducing a solution from the outlet of the body fluid and recovering the nucleated cells captured from the inlet. 容器の面2に対する出口の角度αが45度より大きく135度より小さいことを特徴とする請求項1または2に記載の細胞分離器。 The cell separator according to claim 1 or 2, wherein the outlet angle α with respect to the surface 2 of the container is larger than 45 degrees and smaller than 135 degrees. 容器の面2に対する出口の角度αが垂直であることを特徴とする請求項1または2に記載の細胞分離器。 The cell separator according to claim 1 or 2, wherein the angle α of the outlet with respect to the surface 2 of the container is perpendicular. 血小板も実質的に捕捉する不織布が積層された請求項1から4のいずれかに記載の細胞分離器。 The cell separator according to any one of claims 1 to 4, wherein a nonwoven fabric that substantially captures platelets is laminated. 分離された有核細胞が単核球を含むことを特徴とする請求項1から5のいずれかに記載の細胞分離器。 The cell separator according to any one of claims 1 to 5, wherein the separated nucleated cells include mononuclear cells. 請求項1から6のいずれかに記載の細胞分離器を用いることを特徴とする、細胞分離方法。 A cell separation method using the cell separator according to any one of claims 1 to 6. 低粘度の回収液を用いることを特徴とする、請求項7に記載の細胞分離方法。 The cell separation method according to claim 7, wherein a low-viscosity recovery solution is used. 回収液が生理食塩水、細胞培養用培地、ヒドロキシエチルスターチ、デキストランを含む溶液であることを特徴とする、請求項8に記載の細胞分離方法。 9. The cell separation method according to claim 8, wherein the recovered solution is a solution containing physiological saline, a cell culture medium, hydroxyethyl starch, and dextran.
JP2010271802A 2010-12-06 2010-12-06 Cell separator Pending JP2012120458A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010271802A JP2012120458A (en) 2010-12-06 2010-12-06 Cell separator

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010271802A JP2012120458A (en) 2010-12-06 2010-12-06 Cell separator

Publications (1)

Publication Number Publication Date
JP2012120458A true JP2012120458A (en) 2012-06-28

Family

ID=46502629

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010271802A Pending JP2012120458A (en) 2010-12-06 2010-12-06 Cell separator

Country Status (1)

Country Link
JP (1) JP2012120458A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014119529A1 (en) * 2013-01-29 2014-08-07 株式会社カネカ Method for removing erythrocytes

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60193468A (en) * 1984-03-15 1985-10-01 旭メデイカル株式会社 Leucocyte removal filter
JPH01224325A (en) * 1988-03-03 1989-09-07 Terumo Corp Preparation of leukocyte-separating material
JPH0347131A (en) * 1989-07-14 1991-02-28 Terumo Corp Filter material for capturing leukocyte and production thereof
JPH08108069A (en) * 1994-10-07 1996-04-30 Toyobo Co Ltd Separation of stem cell
WO1998032840A1 (en) * 1997-01-24 1998-07-30 Asahi Medical Co., Ltd. Method for separating cells
JP2000083649A (en) * 1998-09-14 2000-03-28 Terumo Corp Device for separating and recovering cell and separation and recovery of cell
JP2000166541A (en) * 1998-12-03 2000-06-20 Tokai Univ Human undifferentiated hematopoietic stem cell and its separation and separation device
JP2001518792A (en) * 1997-04-08 2001-10-16 ポール・コーポレーション How to collect rare cells from blood products
JP2004121144A (en) * 2002-10-04 2004-04-22 Asahi Medical Co Ltd Method for collecting mononucleosis

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60193468A (en) * 1984-03-15 1985-10-01 旭メデイカル株式会社 Leucocyte removal filter
JPH01224325A (en) * 1988-03-03 1989-09-07 Terumo Corp Preparation of leukocyte-separating material
JPH0347131A (en) * 1989-07-14 1991-02-28 Terumo Corp Filter material for capturing leukocyte and production thereof
JPH08108069A (en) * 1994-10-07 1996-04-30 Toyobo Co Ltd Separation of stem cell
WO1998032840A1 (en) * 1997-01-24 1998-07-30 Asahi Medical Co., Ltd. Method for separating cells
JP2001518792A (en) * 1997-04-08 2001-10-16 ポール・コーポレーション How to collect rare cells from blood products
JP2000083649A (en) * 1998-09-14 2000-03-28 Terumo Corp Device for separating and recovering cell and separation and recovery of cell
JP2000166541A (en) * 1998-12-03 2000-06-20 Tokai Univ Human undifferentiated hematopoietic stem cell and its separation and separation device
JP2004121144A (en) * 2002-10-04 2004-04-22 Asahi Medical Co Ltd Method for collecting mononucleosis

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014119529A1 (en) * 2013-01-29 2014-08-07 株式会社カネカ Method for removing erythrocytes
JPWO2014119529A1 (en) * 2013-01-29 2017-01-26 株式会社カネカ How to remove red blood cells

Similar Documents

Publication Publication Date Title
JP6208186B2 (en) Blood component separation system, separation material
JP5944832B2 (en) Leukocyte or mononuclear cell separation method, separation material
JP5975985B2 (en) Mononuclear cell preparation material, and mononuclear cell preparation method using the preparation material
JP6722023B2 (en) Cell separation filter and method for producing cell concentrate using the same
JP6143746B2 (en) Nucleated cell capture filter or nucleated cell preparation method using the same
JP6379042B2 (en) How to remove red blood cells
JP2013036818A (en) Method of concentrating tumor cell and separation material
JP2012139142A (en) Hematopoietic stem cell separating material or method for separation
JP6621414B2 (en) Filtration device
JP5785713B2 (en) Leukocyte fraction collection device
JP2003304865A (en) Method for separating cell
JP2012120458A (en) Cell separator
JPH08104643A (en) Method for removing erythrocyte
JP2012120457A (en) Cell separating device with function of priming device, and priming method using the same
JP3945725B2 (en) Cell separation method
JP4135894B2 (en) Method, recovery device and recovery system for recovering blood from which leukocytes remaining on the leukocyte removal filter have been removed
JP2020195329A (en) Pressure resistance cell separation filter vessel
McDonald et al. Leukoreduction

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131021

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20141015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141021

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20141022

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141211

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150602